AFP,CA19—9联检在原发性肝癌和肝硬化鉴别诊断中的临床意义

为提高原发性肝癌的诊断率和与肝硬化，其他慢性肝病的鉴别诊断，本文采用放射免疫分析法和免疫放射分析法。对５０例健康体检者、４８例原发性肝癌、３９例肝硬化，３６例其他一肝病患者，分别检验其血清中甲胎蛋白，糖类抗原１９－９肿瘤标志物的含量，结果进行比较。

THE CLINICAL SIGNIFICANCE OF COMBINED DETERMINATION OF SERUM AFP AND CA19-9 IN THE DIFFERENTIAL DIAGNOSIS OF PRIMARY LIVER CANCER AND LIVER CIRRHOSIS

In order to improve the accuracy of the diagnosis of primary liver cancer and the differential diagnosis from liver cirrhosis and other chronic liverdiseases, we tested serum specimens from 50 healthy subjects, 48 patients with primary liver cancer, 39 patients with cirrhosis and 36 patients with other chronic liver diseases for the content of the tumor markers AFP and CA19-9 with RIA and IRMA.The results showed that the levels of AFP and CA19-9 in patients with primary liver cancer were strikingly higher than those in ot.her groups (p<0.01). The positive rate of AFP in the cancer group was 72.9%, compared with 43.5% in cirrhosis anp 13.5% in other chronic liver diseases. The positive rate of CA19-9 was 68.7% in the cancer group, while in cirrhosis was 48.7% and in the group of other chronic liver diseases was 11%. The level of CA19-9 in the cancer group was signifticantly different from those in other grpups(p<0.01).The level in cirrhosis was also different from that in other chronic liver diseases (p<0.05); while there was almost no difference between the levels in chronic liver diseases and the controls(p>0.05). Thus testing of CA19-9 was helpful in the differential diagnosis of various liver diseases. Tn 13 cancer patients with negative AFP, serum CA19-9 was positive in 11 of them. The positive rate was 84.6%. being close to the document report. We believe that testing of serum AFP and CA19-9 is complementary to each other and is of practical diagnostic value.